Related Experiment Video
Updated: Mar 23, 2026
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
Published on: January 20, 2023
Rescue Therapy Using Rituximab for Multiple Sclerosis.
Leticia Berenguer-Ruiz1, Angel P Sempere, Juana Gimenez-Martinez
1*Neurology Service, Hospital Marina Baixa, Villajoyosa; †Neurology Service, Hospital General Universitario de Alicante, Alicante; ‡Neurology Service, Hospital de Denia, Denia; and §Hematology Section, Hospital Marina Baixa, Villajoyosa, Spain.
Rituximab demonstrated safety and effectiveness in relapsing-remitting multiple sclerosis (MS) patients who did not respond to other treatments or had autoimmune conditions. The study found no relapses or MRI activity, with significant improvements in disability and quality of life scores.
Area of Science:
- Neuroimmunology
- Clinical Neurology
- Pharmacology
Background:
- Relapsing-remitting multiple sclerosis (MS) presents challenges in treatment, particularly for patients refractory to standard therapies or with co-existing autoimmune diseases.
- Identifying effective and safe treatment options for these complex MS cases is crucial for improving patient outcomes.
- Rituximab, a B-cell depleting agent, has shown promise in various autoimmune conditions.
Purpose of the Study:
- To evaluate the effectiveness and safety of rituximab in relapsing-remitting MS patients.
- To assess rituximab's utility in patients with treatment-resistant MS or concomitant autoimmune disorders.
- To report clinical and magnetic resonance imaging (MRI) outcomes in this specific patient cohort.
Main Methods:
- An observational study design was employed to assess rituximab's real-world performance.
- Patients included had relapsing-remitting MS and either failed first- or second-line therapies or had contraindications, or presented with concomitant autoimmune diseases.
- Outcomes measured included clinical relapses, Expanded Disability Status Scale (EDSS), EuroQol visual analogue scale (EQ VAS) scores, and MRI activity.
Main Results:
- Twelve patients with relapsing-remitting MS were included, with a mean age of 35 years.
- Ten patients received rituximab due to treatment failure, and two due to idiopathic thrombocytopenic purpura.
- Over a mean follow-up of 40 months, rituximab was well-tolerated with no serious adverse events. No clinical relapses or MRI activity were observed. EDSS scores improved in 11/12 patients, and EQ VAS scores improved in 8/9 patients.
Conclusions:
- Rituximab appears to be a safe and effective treatment for select relapsing-remitting MS patients.
- It offers a viable therapeutic option for those unresponsive to conventional therapies.
- Rituximab may also benefit patients with co-existing autoimmune conditions, warranting further investigation.
More Related Videos
08:48Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023